<DOC>
	<DOC>NCT02603809</DOC>
	<brief_summary>The main objective of the study is to explore the effects of ERA - at different dose strengths - on the efficacy, safety and tolerability in subjects with essential hypertension</brief_summary>
	<brief_title>Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Signed informed consent prior to any studymandated procedure Mildtomoderate essential hypertension with or without ongoing antihypertensive treatment(s) No contraindication to stop (according to label) antihypertensive treatment(s) Women of childbearing potential must have a negative pregnancy test and use of reliable methods of contraception Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP; measured by OBPM) â‰¥ 180/110 mmHg, respectively. Secondary hypertension Known hypertensive retinopathy greater than KeithWagener Grade 2 Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within 12 months prior to randomization Unstable angina within 6 months prior to randomization Heart failure New York Heart Association class III and IV Valvular defects (such as severe aortic or mitral valve disease) and/or hemodynamically relevant rhythm disturbances Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident within 6 months prior to randomization. Subjects working night shifts Body mass index &lt; 20 kg/m2 or &gt; 40 kg/m2 Treatment with any medication which may affect BP (e.g., treatment of psychiatric diseases, ophthalmic preparations) Treatment with strong cytochrome P450 3A4 (CYP3A4) isoenzyme inhibitors or inducers Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1 month prior to Screening (Visit 1) Treatment with another investigational treatment within 1 month prior to Screening (Visit 1) Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>